TABLE 1.
Isolate | TA9730 | TA9734 | TA9759 | TA9832 | ||||
---|---|---|---|---|---|---|---|---|
Patient/environment | Patient 1 | Patient 2 | Environment | Patient 3 | ||||
Isolation date | 2020.09.02 | 2020.09.04 | 2020.09.08 | 2020.09.09 | ||||
Gender | Female | Female | N/A c | Female | ||||
Age (years) | 5 | 5 | N/A | 4 | ||||
Origin | Feces | Feces | Waste channel | Biliary drain | ||||
MIC (µg/mL) a | ||||||||
Ampicillin-sulbactam | >16 | R | >16 | R | >16 | R | >16 | R |
Piperacillin-tazobactam | >64 | R | >64 | R | >64 | R | >64 | R |
Cefazolin | >16 | R | >16 | R | >16 | R | >16 | R |
Cefotiam b | >4 | − | >4 | − | >4 | − | >4 | − |
Cefotaxime | >32 | R | >32 | R | >32 | R | >32 | R |
Ceftazidime | >16 | R | >16 | R | >16 | R | >16 | R |
Cefepime | >16 | R | >16 | R | >16 | R | >16 | R |
Cefmetazole | >32 | R | >32 | R | >32 | R | >32 | R |
Moxalactam | >32 | R | >32 | R | >32 | R | >32 | R |
Imipenem | >8 | R | 8 | R | >8 | R | 8 | R |
Meropenem | >8 | R | >8 | R | >8 | R | >8 | R |
Doripene | >8 | R | >8 | R | >8 | R | >8 | R |
Aztreonam | ≤1 | S | ≤1 | S | ≤1 | S | ≤1 | S |
Gentamicin | >8 | R | >8 | R | >8 | R | >8 | R |
Tobramycin | >8 | R | >8 | R | >8 | R | >8 | R |
Amikacin | >32 | R | >32 | R | >32 | R | >32 | R |
Ciprofloxacin | ≤0.06 | S | 0.5 | I | ≤0.06 | S | 0.5 | I |
Levofloxacin | ≤0.12 | S | 2 | R | ≤0.12 | S | 1 | I |
Minocycline | ≤1 | S | 2 | S | ≤1 | S | 2 | S |
Sulfamethoxazole/trimethoprim | >80 | R | >80 | R | >80 | R | >80 | R |
Carbapenemase production | NDM (+) | NDM (+) | NDM (+) | NDM (+) |